Daiichi Sankyo Europe GmbH

Featured Stories

For the last nine years Daiichi Sankyo has supported young graduates in Pharmaceutical Sciences from the Ludwig-Maximilians-University in Munich (LMU). In 2017, Kristina Eiglmeier and Martin Müller were awarded the "Master Prize" read more...

The new Daiichi Sankyo Group’s Value Report is now available! The report includes business facts & figures, information about Daiichi Sankyo’s growth potential, CSR activities and much more. read more...

Featured News

Date	Description
18/05/2018 Products	LIXIANA® ▼ (edoxaban) shows reduced rate of a variety of types of intracranial haemorrhage compared to warfarin in new sub-analysis presented at the European Stroke Organisation Conference 2018	PDF
17/05/2018 Research	Daiichi Sankyo to Present New Data on Multiple Compounds Including Antibody Drug Conjugates DS-8201 and U3-1402 at 2018 American Society of Clinical Oncology (ASCO) Annual Meeting	PDF
17/05/2018 Research	Zymeworks and Daiichi Sankyo Expand Immuno-Oncology Collaboration Focused on Bispecific Antibodies	PDF
08/05/2018 Research	Daiichi Sankyo Announces Single Agent Quizartinib Significantly Prolongs Overall Survival Compared with Chemotherapy in Patients with Relapsed/Refractory AML with FLT3-ITD Mutations (QuANTUM-R Study)	PDF
04/04/2018 Research	Daiichi Sankyo and DarwinHealth Enter Exclusive Research Collaboration for Novel Cancer Target Initiative	PDF
show all

Dear User, This website provides you with information only for healthcare professionals. According to the drug promotion code, we are only able to allow healthcare professionals like physicians and pharmacists to have full access to our website. To visit our page please login.

Daiichi Sankyo
Doc Check

Support for Young Talents

Value Report 2017